The therapeutic and toxic effects of drugs are often generated through effects on distinct cell types in the body. Selective delivery of drugs to specific cells or cell lineages would, therefore, have major advantages, in particular, the potential to significantly improve the therapeutic window of an agent. Cells of the monocyte-macrophage lineage represent an important target for many therapeutic agents because of their central involvement in a wide range of diseases including inflammation, cancer, atherosclerosis, and diabetes. We have developed a versatile chemistry platform that is designed to enhance the potency and delivery of small-molecule drugs to intracellular molecular targets. One facet of the technology involves the selective delivery of drugs to cells of the monocyte-macrophage lineage, using the intracellular carboxylesterase, human carboxylesterase-1 (hCE-1), which is expressed predominantly in these cells. Here, we demonstrate selective delivery of many types of intracellularly targeted small molecules to monocytes and macrophages by attaching a small esterase-sensitive chemical motif (ESM) that is selectively hydrolyzed within these cells to a charged, pharmacologically active drug. ESM versions of histone deacetylase (HDAC) inhibitors, for example, are extremely potent anticytokine and antiarthritic agents with a wider therapeutic window than conventional HDAC inhibitors. In human blood, effects on monocytes (hCE-1-positive) are seen at concentrations 1000-fold lower than those that affect other cell types (hCE-1-negative). Chemical conjugates of this type, by limiting effects on other cells, could find widespread applicability in the treatment of human diseases where monocyte-macrophages play a key role in disease pathology.
Introduction
One of the recurring issues with modern, intracellularly acting drugs is that their target enzymes are often part of signaling pathways that are active in most cells in the body. Although pharmacological benefits are often evident with such agents in disease models, their effects on cells uninvolved in the disease process often lead to levels of toxicity in humans that limit their utility to the most severely affected patients. It has long been a "holy grail" of pharmacology to target agents specifically to the cell type responsible for disease development. A range of approaches has previously been investigated in this regard including immunoliposomal systems based on monoclonal antibodies, sugar-dependent systems that take advantage of cell-specific lectins, and receptor-dependent systems that allow the targeting of cells bearing specific integrins by RGD-containing peptides (Pasqualini et al., 1997; Dubowchik and Walker, 1999; Paulos et al., 2004; Kontermann, 2006; Aouadi et al., 2009) . Although some success has been achieved by these means, the approaches have been limited to parenterally acting drugs, often chemotherapeutic agents that are administered acutely for life-threatening diseases such as cancer. There remains a need for a more robust and general method of selective drug delivery that can be applied to multiple drug types administrable by mouth on a long-term basis. If such an approach were found, it would have the potential to improve the therapeutic window of drugs by limiting their effects to those cells specifically involved in the disease pathology. This could lead to the resurrection of certain drug classes whose pharmacological effects on other cell types have led to toxicity that has precluded drug development.
Human cells express three intracellular carboxylesterases that convert neutral, membrane-permeant esters into charged acid products (Imai, 2006) . One of these, human carboxylesterase-1 (hCE-1), has a restricted expression profile in humans (Satoh et al., 1999; Uphoff and Drexler, 2000; Su et al., 2004; Li et al., 2005) , with cells of the monocytemacrophage lineage being the principal source of the enzyme outside the hepatocyte. We postulated that tissue exposure to a drug-ester conjugate that is a specific substrate for hCE-1 might lead to intracellular ester hydrolysis and production of a pharmacologically active acid only within those cell types. Because of its charged nature, the acid would have limited ability to leave the cell and, over time, would be expected to accumulate to high intracellular levels. This would yield benefits in terms of drug potency and longevity of action but, importantly, would also direct the pharmacological effects to cells expressing hCE-1, such as monocytes and macrophages.
Tangential support for the proposed approach comes from our studies with the novel anticancer agent tosedostat (2S-[2R-(Shydroxy-hydroxycarbamoyl-methyl)-4-methylpentanoyl-amino]-2-phenylethanoic acid cyclopentyl ester (CHR-2797)), which contains an amino acid ester motif that undergoes intracellular hydrolysis to its acid (Krige et al., 2008) . Administration of tosedostat to human cells in vitro and in vivo leads to the intracellular build-up of the corresponding acid and improved potency and longevity of action. In the case of tosedostat, however, the amino acid ester moiety is hydrolyzed by all three carboxylesterases and, in addition, is required for high-affinity binding to its pharmacological target. To deliver a wide range of intracellularly acting drugs to hCE-1-expressing cells, an hCE-1-selective motif has to be attached to a drug at a position that does not significantly disrupt the target enzyme-inhibitor interaction. In this article, we describe a robust method of selectively delivering a range of intracellularly acting agents to monocytes and macrophages using an hCE-1-selective amino acid ester motif.
Materials and Methods

Chemistry.
1 H NMR spectra were determined with Bruker (Newark, DE) AV spectrometers at 300 or 400 MHz. Chemical shifts are reported in ppm relative to residual chloroform (7.26 ppm) or dimethyl sulfoxide (2.49 ppm) as internal reference with coupling constants (J) reported in Hz. The peak shapes are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. Analytical HPLC/MS was performed on an Agilent HP1100 LC system (Agilent Technologies, Santa Clara, CA) using reversephase Luna C18 columns (3 m, 50 ϫ 4.6 mm), gradient 5 to 95% B (A ϭ water/0.1% formic acid; B ϭ acetonitrile/0.1% formic acid) over 2.25 min, flow ϭ 2.25 ml/min. UV spectra were recorded at 220 and 254 nm using a G1315B DAD detector (Agilent Technologies). Mass spectra were obtained over the range m/z 150 to 800 on a LC/MSD SL G1956B detector (Agilent Technologies). Data were integrated and reported using ChemStation and ChemStation Data Browser software (Agilent Technologies). The purity of all the compounds was found to be above 95%. Reverse-phase HPLC purifications were performed on Gilson (Villier Le Bel, France) preparative systems using reverse-phase Axia prep Luna C18 columns (Phenomenex, Torrance, CA) (10 m, 100 ϫ 21.2 mm), gradient 0 to 100% B (A ϭ water/0.05% trifluoroacetic acid, B ϭ acetonitrile/0.05% trifluoroacetic acid) over 10 min, flow ϭ 25 ml/min, monitored by UV detection at 254 nm. Thin-layer chromatography analysis was performed with Kieselgel 60 F 254 (Merck, Darmstadt, Germany) plates and visualized using UV light. Details of the synthesis of parental and esterase-sensitive motif (ESM)-related molecules are in Supplemental Data.
Animals. The hCE-1 knock-in transgenic mouse was generated by Genoway (Lyon, France) by targeted insertion of the expression cassette into the expression permissive hprt locus on the X chromosome by homologous recombination. Expression of the hCE-1 transgene was driven by the human CD68 promoter (provided by Dr. David Greaves, Oxford University, Oxford, United Kingdom), which has previously been shown to direct transgene expression in macrophages of transgenic mice (Gough et al., 2001) . Details are provided in Supplemental Data.
Assessment of the Accumulation of Ester-Derived Acid in Intact Human Tumor Cells. Cells (4 ϫ 10 4 /ml) were incubated at 37°C in culture medium containing 6 M compound. Incubations were terminated by centrifugation (300g; 5 min; 4°C). Supernatants were added to four volumes of HPLC-grade acetonitrile. After decanting the supernatant, the residual cell pellet (1 ϫ 10 6 cells) was extracted into 1 ml of acetonitrile. Samples were analyzed for the ester and acid metabolite at room temperature by LC/MS/MS (Sciex API3000; Sciex, Warrington, UK). Chromatography was based on an AceCN (Hichrom, Theale, UK) (75 ϫ 21 mm) column with a 5 to 95% (v/v) acetonitrile, 0.1% (v/v) formic acid mobile phase.
Assessment of the Effect of Drugs on LPS-Induced TNF␣ Production in Human Blood. Human heparinized blood was diluted with an equal volume of RPMI 1640 medium and then aliquoted into 96-well microtiter plates (100 l/well). Inhibitors (5-10,000 nM; diluted in RPMI 1640 medium) were added and, after incubation for 2 h at 37°C, TNF␣ production was stimulated by the addition of LPS (100 ng/ml) for 6 h at 37°C. Plates were then centrifuged (3 min, 800g) and TNF␣ present in the supernatant measured using a QuantiGlo chemiluminescent enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN).
Assessment of the Effect of Drugs on Cytokine Gene Expression in Human Blood. Human heparinized blood was diluted with an equal volume of RPMI 1640 medium and aliquoted (0.5 ml) into 12-well dishes. Vehicle/compounds were added (triplicate samples) and incubated for 2 h at 37°C before the addition of LPS (100 ng/ml) for 6 h. Red cells were then lysed and mRNA was stabilized by the addition of PAXgene Blood RNA Reagent (PreAnalytiX, Hombrechtikon, Switzerland). RNA was isolated and purified using half reaction volumes of a PAXgene Blood RNA Kit (PreAnalytiX). RNA was eluted and used for cDNA synthesis using a High Capacity cDNA RVT Kit (Applied Biosystems, Foster City, CA). After dilution in water, cDNA was stored arrayed in 96-well deep well plates (Axygen, Union City, CA), and 10 l of cDNA was used as a template for quantitative PCR using SYBR Green PCR Master Mix (Applied Biosystems) in a 25-l reaction using primers (200 nM). Quantitative PCR was performed on an ABI 7300 Real Time PCR System (Applied Biosystems). Expression levels were normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase by ⌬Ct methodology, and the results were expressed relative to negative controls. The primers used are described in Supplemental Data.
Monocyte/Macrophage Targeting of Intracellular Drugs
Assessment of the Effect of Drugs on Cell Proliferation. The method used has been described previously (Krige et al., 2008) .
Assessment of the Effect of Drugs on LPS-Induced TNF␣ Production in Human THP-1 Cells. THP-1 cells (4 ϫ 10 4 /well) in 96-well microtiter plates were incubated with inhibitors (5-10,000 nM) for 2 h at 37°C. TNF␣ production was stimulated by the addition of LPS (1 g/ml) for 6 h at 37°C. Plates were then centrifuged (3 min, 800g) and TNF␣ present in the supernatant was measured using a QuantiGlo chemiluminescent enzyme-linked immunosorbent assay kit (R&D Systems).
Esters as Substrates for Recombinant hCE-1 and hCE-2. Recombinant hCE-1 and hCE-2 (Ͼ95% pure by SDS-polyacrylamide gel electrophoresis) were obtained from Dr. P. Sanghani (Indiana University School of Medicine, Indianapolis, IN) and stored at 4°C in 50 mM potassium phosphate buffer, pH 7.5, with 10% (v/v) ethylene glycol. The activities of the hCE-1 and hCE-2 preparations were 5.66 and 97.2 U/mg protein, respectively (1U ϭ moles 4-methyl umbelliferyl acetate converted per minute per milligram at 37°C). Hydrolysis assays were conducted in triplicate at 37°C by addition of compound (2.5 M) to recombinant hCE-1 or hCE-2 (0.0025 U) in potassium phosphate buffer, pH 7.4/40 mM potassium chloride. Samples were taken at various time points and the reaction was stopped by the addition of three volumes of acetonitrile. Samples were then analyzed for parent ester and acid metabolite at room temperature by LC/MS/MS.
Esters as Substrates for Carboxylesterases in Cell Lysates. Cell lysates (10 9 cells in 35 ml) were prepared by nitrogen cavitation (700 psi; 50 min; 4°C) in 10 mM Tris-HCl, pH 7 buffer containing NaCl (130 mM) and CaCl 2 (0.5 mM). This homogenate was supplemented with the following cocktail of inhibitors: leupeptin, 0.5 g/ml; aprotinin, 1 g/ml; E64 [(2S,3S)-3-(N-{(S)-1-[N-(4-guanidino-butyl) carbamoyl]3-methylbutyl}carbamoyl)oxirane-2-carboxylic acid], 3 g/ml; pepstatin, 1 g/ml; bestatin, 50 g/ml, and chymostatin, 20 g/ml. Esterase activity in lysates was measured by adding homogenate (equivalent to 4 ϫ 10 5 cells) to ester (2.5 M) in 25 mM Tris-HCl buffer, pH 7.5/125 mM NaCl. After incubation for various times at 37°C, the reaction was stopped by the addition of acetonitrile. Samples were then analyzed for parent ester and acid metabolite at room temperature by LC/MS/MS.
Assessment of the Effect of Drugs on Anisomycin-Stimulated MAPKAPK-2 Phosphorylation in Intact U-937 and HuT-78 Cells. U-937 and HuT-78 cells, grown in RPMI 1640 medium, with 10% fetal calf serum, 1% glutamine, and 1% penicillin/ streptomycin were treated with vehicle/compound for 4 h before adding anisomycin (10 M, 30 min) or vehicle. Cells were harvested on ice, washed twice, and lysed in SDS lysis buffer (62.5 mM Tris, pH 6.8, 2% SDS, 10% glycerol, and 50 mM dithiothreitol supplemented with protease and phosphatase inhibitors according to the manufacturer's instructions; Novex/Invitrogen, Carlsbad, CA). After sonication and centrifugation to remove cell debris, samples were run on 10% BT MOPS gels (Novex/Invitrogen). Phosphorylation of MAP-KAPK-2 was measured from the resulting nitrocellulose membranes following the manufacturer's instructions for the specific primary antibody (Cell Signaling Technology, Danvers, MA). Glyceraldehyde-3-phosphate dehydrogenase was used as a loading control. Visualization of the signal was carried out using enhanced chemiluminescence reagent and film (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK).
Enzyme Assays. The ability of the various parental or ESMbased drugs to inhibit enzyme [histone deacetylase (HDAC), HSP-90, IB kinase 2, and p38 MAP kinase ␣] activity was measured as described in Supplemental Data.
Mouse Anticollagen Antibody Arthritis Model. An anticollagen antibody-induced arthritis model was conducted in littermate wild-type (w/t) or hCE-1 transgenic (t/g) mice. Details of the methodology and scoring system are described in Supplemental Data.
Results
Identifying an hCE-1-Selective Chemical Motif. Initial studies focused on the identification of an amino acid ester motif that was selectively hydrolyzed by hCE-1. Synthesis of a range of compounds in which a phenylalanine cyclopentyl ester was attached through a variety of linkers to a phenyl substituent led to the discovery that an amine linkage, rather than the amide linkage found in tosedostat, led to ester hydrolysis in lysates of hCE-1-expressing, but not non-hCE-1-expressing, cells (Table 1) . ESM-Based HDAC Inhibitors. Next, a range of analogs of the HDAC inhibitor vorinostat (SAHA) (Richon et al., 1998) were prepared in which the phenyl ring was substituted with different amino acid esters through amine linkages. As exemplified by CHR-3111 and CHR-2875 (Table 2) , ring substitution, remote from the critical hydroxamic acid binding site (Richon et al., 1998; Weinmann and Ottow, 2004) , had little impact on HDAC inhibitory activity. For hCE-1
Ϫve cell lines (KG-1, HuT-78, and MOLT-4), antiproliferative potency of the HDAC inhibitors was similar to SAHA (Table 2) , but in hCE-1 ϩve myelomonocytic tumor cell lines (THP-1, MV4 -11 and U-937 cells) (see Supplemental Table  S1 ), however, there was a 10-to 30-fold increase in antiproliferative potency (Table 2 ). In an isolated enzyme assay, CHR-2875 and CHR-3111 were hydrolyzed by hCE-1 but only to a very limited extent by the ubiquitously expressed hCE-2 (Table 3) . Moreover, lysates of U-937 cells, but not of non-hCE-1-expressing cells such as HuT-78 cells, also selectively hydrolyzed CHR-2875 and CHR-3111 and, when intact cells were exposed to the agents, measureable acid derived from these esters could be detected only in intact U-937 cells (Table 3 ). The rate of hydrolysis of CHR-3111 by different leukemic cell lysates correlated well with the extent of expression of hCE-1 in these cell lines (Supplemental Table S1 ). When the cyclopentyl ester found in CHR-3111 and CHR-2875 was changed to the less hydrolysable t-butyl ester (CHR-2908 and CHR-6511) (Table 2) neither hCE-1 nor lysates from cells expressing it were able to produce significant amounts of the acid product ( Table 3) . As expected, the selective antiproliferative effect on hCE-1-expressing cell lines was lost in cells treated with the t-butyl ester analogs ( Table  2 ), demonstrating that significant ester hydrolysis was man- * Values shown are means of at least three estimations of HDAC potency using HeLa cell nuclear extract as the source of HDAC activity. ** Values shown are means derived from experiments conducted over 72 h using ͓ datory for the potent and cell-selective effects of CHR-2875 and CHR-3111. Addition to cells of the charged acid products, CHR-2880 and CHR-3112, had no effect on cell proliferation in any cell line (Table 2) . hCE-1-Dependent Amino Acid Ester Motifs Are Versatile. We next investigated whether the same ESM found in CHR-3111 (a leucine-cyclopentyl ester) was also selectively hydrolyzed by hCE-1-expressing cells when attached to a range of chemically diverse drugs that target different intracellular enzymes. Based on a good understanding of how drugs targeting HSP-90, p38 MAP kinase, and IB kinase 2 bind to their targets, analogs were designed and synthesized in which the ESM group was attached at a position remote from the drugs' binding interface with their target enzymes (Alonso-Alija et al., 2003; Baxter et al., 2004; Chessari et al., 2006) . Hydrolysis of these ESM variants was at least 500-fold increased in lysates derived from hCE-1-expressing cell lines relative to those from cells lacking this carboxylesterase (Table 4) . Moreover, the acid products of the intracellular carboxylesterase reaction retained the potency of the parental agent against the intracellular target (Table 4) .
ESM-Based p38 MAP Kinase Inhibitors. When added to intact cells, the ESM-based p38 MAP kinase inhibitor CHR-5623 (Table 4) , for example, led to accumulation of its corresponding acid, N- (2-{4-[6-amino-5-(2,4- -5668) , in U-937 cells (hCE-1 positive) but not in HuT-78 cells (hCE-1 negative) (Table 5 ). Regarding this selective accumulation, the addition of CHR-5623 to these two cell types led to very potent inhibition of anisomycin-stimulated MAPKAPK-2 phosphorylation (a downstream target of p38 MAP kinase) (Winzen et al., 1999) only in U-937 cells (Table 5 ). The parent p38 MAP kinase inhibitor, CHR-3464 (Table 4) , failed to elicit such cell-selective effects (Table 5) .
ESM-Based HSP-90 Inhibitors. Similar cell selectivity data were seen when a targeted HSP-90 inhibitor, CHR-7296 (Supplemental Table S2 ), was compared with a conventional inhibitor, SNX-2112 (Supplemental Table S2 ) (Okawa et al., 2009) . Both compounds had similar potencies in an LPSstimulated TNF␣ production assay carried out in the monocyte/macrophage human tumor cell line, THP-1 (the IC 50 values for SNX-2112 and CHR-7296 were both approximately 50 nM) or in human blood (the IC 50 values for SNX- (Fig. 1) .
Thus, ESMs that confer hCE-1-dependent hydrolysis and cellular effects on SAHA-based HDAC inhibitors confer the same qualities on a diverse set of chemicals that inhibit different intracellular targets. These data suggest that it should be possible to target a variety of intracellularly acting drugs to cells of the monocyte-macrophage lineage, which are implicated in a range of human pathologies.
ESM-Based Drugs Demonstrate Monocyte-Specific Effects in Human Blood. In human blood, only monocytes have been shown to express hCE-1 (Su et al., 2004; Liu et al., 2006; see Supplemental Fig. S1 ). To investigate whether selective delivery to monocytes could be achieved by ESM targeting, samples of human blood were treated with both parental and macrophage-targeted versions of HDAC inhibitors and their impact on protein acetylation was measured directly in FACS-identified blood cells. The data in Fig. 2 demonstrate that the targeted HDAC inhibitor, CHR-2875, but not its poorly hydrolysable analog, CHR-2908, was more potent than SAHA in its ability to enhance protein acetylation in the monocyte cell population in blood and, unlike SAHA, showed selectivity for the monocyte population versus lymphocytes and granulocytes. The selective effects seen with CHR-2875 were seen to a greater extent with an unrelated HDAC inhibitor, CHR-4487 (Supplemental Table S3 ), which contains a strongly hydrolysable cyclohexylglycine amino acid ester motif (Supplemental Table S3 ). When incubated with human blood, CHR-4487 was ϳ1000-fold selective for monocytes over either lymphocytes or granulocytes (Fig.  2) . The t-butyl ester analog of CHR-4487, CHR-5355, which, like CHR-2908, is poorly hydrolyzed by lysates of hCE-1-positive cells (Supplemental Table S3 ), did not show any cell-selective effects (Fig. 2) . HDAC inhibitors such as SAHA are known to exhibit anticytokine effects in human blood or blood cell studies (Leoni et al., 2002 (Leoni et al., , 2005 . The functional impact of monocyte-selective delivery can be clearly seen when the anticytokine effects of HDAC inhibitors were investigated in LPS-stimulated human blood. Agents showing monocyte-selective effects were significantly more potent as inhibitors of TNF␣ production than parental or unhydrolysable inhibitors: despite being 4-fold weaker than SAHA as an HDAC inhibitor, the IC 50 for CHR-4487 as an inhibitor of LPS-induced TNF␣ production was ϳ20-fold lower (16 nM versus 290 nM) (Supplemental Table S3 ).
To study the effects of p38 MAP kinase inhibitors in human blood, it is necessary to activate the pathway and monitor the cell-selective impact of inhibitors on the phosphorylation of MAPKAPK-2, an immediate downstream substrate of p38 MAP kinase (Winzen et al., 1999) . LPS activates MAPKAPK-2 phosphorylation in FACS-identified monocytes and granulocytes, but not in lymphocytes. The macrophage- jpet.aspetjournals.org targeted p38 MAP kinase inhibitor, CHR-5623, was approximately 100-fold selective for monocytes versus granulocytes when inhibition of MAPKAPK-2 phosphorylation was measured after LPS addition (Fig. 3) . Its parent, CHR-3464, showed no such selectivity and, despite its 100-fold better activity than CHR-5623 as a p38 MAP kinase inhibitor (Table 5), was 10-fold weaker than the latter as an inhibitor of LPS-stimulated monocyte MAPKAPK-2 phosphorylation (Fig. 3) . Thus, despite the fact that monocytes comprise only 2 to 8% of the leukocytes present in blood, targeted HDAC and p38 MAP kinase inhibitors, but not conventional inhibitors, were able to exert profoundly cell-selective effects on this cell population in human blood.
Monocyte-Targeted and Parental Inhibitors Show Distinct Effects in Cytokine Gene Expression Studies.
The range of pharmacological effects of monocyte-targeted agents are likely to be distinct from those of nontargeted agents because the latter can act on cells outside of the monocyte-macrophage lineage. This was investigated by examining the effects of both types of agent on gene expression changes induced by either LPS or a combination of phorbol myristate acetate (PMA) and ionomycin in human blood. The former stimulates multiple signaling pathways predomi- With LPS as the stimulant, qualitative differences between the targeted and parental HDAC inhibitors in terms of the effects on cytokine gene expression were rare: a portion (ϳ10%) of the LPS-induced expression of IL-1␤ and IL-8 was insensitive to CHR-4487, the monocyte-targeted HDAC inhibitor, but sensitive to SAHA, the parental inhibitor (Fig.  4a) , perhaps reflecting granulocyte-derived gene expression. More noteworthy, however, were the effects of the two compounds on LPS-stimulated G-CSF expression, where, unlike SAHA, which gave almost complete inhibition of expression at higher concentrations, CHR-4487 induced a biphasic effect on expression, with potent inhibition of G-CSF expression (3-10 nM) being almost completely reversed at higher concentrations (100 -300 nM) (Fig. 4a) . When a combination of PMA and ionomycin was used to stimulate a wider cohort of cells in blood, differences between the parental and targeted agents became more marked. The parental HDAC inhibitor SAHA had no significant effect on the PMA/ionomycin-induced expression of these cytokine genes (Fig. 4a) , whereas CHR-4487 enhanced the stimulated expression of IL-1␤ and IL-10. The expression of G-CSF, which was not itself altered by PMA/ionomycin, was enhanced 100-fold by the monocytetargeted HDAC inhibitor. With the HSP-90 inhibitors, SNX-2112 (conventional) and CHR-7296 (ESM), there was, again, little qualitative difference between the two compounds with LPS as the stimulant (Fig. 4b) . However, with PMA/ionomycin as the stimulant, TNF␣ and interferon-␥ expression was inhibited (70 -80%) by the conventional agent (SNX-2112) but completely unaffected by the monocyte-targeted agent, CHR-7296, even at concentrations 30-fold higher (Fig. 4b) .
Creation of an hCE-1 "Knock-In" Mouse. Expression data (Lattin et al., 2008) indicate that neither mouse blood cells nor, for example, the murine monocyte-macrophage cell line RAW 264.7 selectively express an hCE-1 homolog (also see data from wild-type mice in Supplemental Fig. S2 indicating that CHR-4487 is not monocyte-selective). To circumvent this problem and assess the in vivo efficacy of these macrophage-targeted compounds, we created a transgenic mouse strain in which hCE-1 was expressed predominantly in a monocyte-macrophage lineage-selective way (driven by a human CD68 promoter; Gough et al., 2001 ) (see Supplemental Data). Wild-type littermate animals emerging from this breeding program served as controls and allowed a definitive assessment of how the targeting of HDAC inhibitors affected the disease process. Histone acetylation was assessed in blood from wild-type and transgenic mice treated in vitro with either SAHA or CHR-4487. SAHA treatment increased histone acetylation at approximately equivalent concentrations in all blood cell types from both strains of mice. In wild-type mouse blood, CHR-4487, similarly, showed no selective effects on histone acetylation in the FACS-identified blood cell populations (Supplemental Fig. S2 ). In contrast, CHR-4487 increased acetylation in the monocyte population of hCE-1 "knock-in" mice to a greater extent than the other blood cell types studied (Supplemental Fig. S2) . No difference in lymphocyte protein acetylation was seen between the two mouse strains when blood was incubated with CHR-4487 (Supplemental Fig. S2 ). These data indicate that the selective effects of macrophage-targeted HDAC inhibitors seen in human whole blood can be recapitulated, to a large degree, in blood from these transgenic mice.
Administration of CHR-4487 (10 mg/kg, i.p.) to wild-type or transgenic mice led to the short-lived appearance of the ester in plasma, followed by a more sustained circulating level of its acid product, CHR-4495 (Supplemental Fig. S3 ). The impact of the selective accumulation of CHR-4495 in the circulating monocytes of the transgenic animals was assessed indirectly by measuring the level of protein acetylation in the different blood cell populations. A rapid and sustained increase in this parameter in FACS-identified monocytes, but not lymphocytes, was readily seen (Supplemental Fig. S3) . A smaller, but significant, effect on granulocyte protein acetylation was also noted (Supplemental Fig. S3 ). As expected from previous data with tosedostat, the pharmacological effect of CHR-4487 on circulating monocytes substantially outlived circulating ester exposure because of retention of the product acid within these cells (Löwenberg et al., 2010) .
In Vivo Arthritis Studies Using Monocyte/Macrophage-Targeted and Parental HDAC Inhibitors. When both wild-type and transgenic mice were inoculated with a cocktail of anticollagen type II antibodies (Nandakumar et al., 2003) , followed 3 days later by an LPS injection, all animals developed clinical signs of arthritis by day 6 (Fig. 5) . Treatment of mice with daily doses of SAHA inhibited arthritis development in both strains of mice only at the highest dose of SAHA studied (100 mg/kg/day). Once-daily intraperitoneal dosing with CHR-4487 (3 or 10 mg/kg/day) had no effect in wild-type animals but, in contrast, CHR-4487 (1, 3 or 10 mg/kg/day i.p.) significantly inhibited arthritis development in transgenic animals (Fig. 5) . Doses of 3 and 10 mg/ compound . nM relative to -ve cont Fig. 4 . The effects of conventional and macrophage-targeted HDAC inhibitors and HSP-90 inhibitors on cytokine gene expression in human blood. a, human blood was incubated with a conventional (SAHA, blue symbols) or macrophage-targeted (CHR-4487, red symbols) HDAC inhibitor for 2 h at 37°C. After treatment with either LPS (100 ng/ml) (left) or a combination of PMA (20 nM) and ionomycin (1 M) (right) for 6 h, RNA was collected, stabilized, and extracted using the PAXgene Blood RNA system. After preparation of cDNA samples, real-time PCR was used to quantify mRNA expression in the presence or absence of drugs. b, human blood was incubated with a conventional (SNX-2112, blue symbols) or macrophage-targeted (CHR-7296, red symbols) HSP-90 inhibitor for 2 h at 37°C. After treatment with either LPS (100 ng/ml) (left) or a combination of PMA (20 nM) and ionomycin (1 M) (right) for 6 h, RNA was collected, stabilized, and extracted using the PAXgene Blood RNA system. After preparation of cDNA samples, real-time PCR was used to quantify cytokine/chemokine mRNA expression in the presence or absence of drugs. Values shown are means Ϯ S.D. for a single experiment, which was replicated two to five times. kg/day almost completely inhibited both clinical and histological signs of arthritis ( Fig. 5 and Supplemental Fig. S4 ). It is noteworthy that other studies demonstrated that transgenic mice tolerated at least 30 mg/kg/day i.p. CHR-4487 well, gaining ϳ5% of the starting weight over 7 days of treatment (Supplemental Table S4 ). In contrast, at the effective dose of 100 mg/kg/day, SAHA-treated animals lost ϳ5% body weight within 7 days (Supplemental Table S4 ). In this model, therefore, a therapeutic window of at least 30-fold was seen with CHR-4487. Thus, targeting of HDAC inhibitors to hCE-1-positive cells has both retained the antiarthritic effect seen with SAHA and has widened the therapeutic window of this class of agent.
Discussion
A range of approaches has previously been investigated to achieve cell targeting, including the use of immunoliposomal, sugar-and receptor-dependent systems (Pasqualini et al., 1997; Dubowchik and Walker, 1999; Paulos et al., 2004; Kontermann, 2006; Aouadi et al., 2009 ). In the current approach, receptor-based cell targeting is eschewed and the selective expression of an intracellular enzyme (hCE-1) is harnessed to convert a prodrug into a pharmacologically active acid species only in hCE-1-expressing cells. The irreversible nature of this hydrolysis, and the physicochemical properties of the poorly membrane-penetrant acid produced, leads to a high intracellular concentration of the active acid, which delivers the cell-selective effect. The striking cell-selective effects seen with monocyte-targeted agents such as CHR-4487 in human blood reflect the exquisite hydrolytic selectivity of hCE-1 for certain amino acid ester constructs and occur despite the fact that monocytes constitute a very small proportion of the carboxylesterase-containing cell pool present in blood. Moreover, the selectivity also occurs despite the fact that CHR-4487 is as pharmacologically active in its ester proform as it is in its acid product form. As a neutral species, the ester will penetrate all cells, and it might have been expected to generate effects on neutrophils and lymphocytes commensurate with its innate activity against the HDAC enzyme. The monocyte-specific effects seen in blood with agents such as CHR-4487 demonstrate that this is not the case and may be explained by the extremely efficient intramonocytic processing of the low concentrations of free (nonplasma protein bound) ester present in human blood that limit ester availability to other cell types. These data are reinforced by the studies conducted in blood in which cytokine gene expression patterns are examined after treatment with conventional and selective inhibitors of different intracellular targets. The results seen are entirely consistent with the notion that cell-selective drugs might be expected to exhibit a different, and potentially advantageous, therapeutic profile compared with nontargeted homologues.
Ideally, any cell-selective delivery system should be flexible, compatible with as many drug classes as possible and suitable for either oral or parenteral routes of administration. Data derived from ESM versions of many drug classes indicate that it is possible to selectively hydrolyze and, hence, deliver a range of drug classes to intracellular targets within the monocyte-macrophage lineage using hCE-1-hydrolysable chemical motifs. Such ESM-based drugs retain the enzyme potency of the parent molecule in their intracellular acid form and, as a result, demonstrate cell-selective potency advantages relative to their parents. The potency advantages seen with these targeted agents are often best seen in human blood and, using the technology, HDAC inhibitors, for example, become very potent anticytokine agents. Parental HDAC inhibitors are known to have such effects (Leoni et al., 2002 (Leoni et al., , 2005 , but their usefulness in diseases outside of cancer is likely to be limited by their inherent low therapeutic ratio, confirmed again in this work. The in vivo studies conducted with the hCE-1 knock-in mice demonstrate that the anticytokine effects of macrophage-targeted HDAC inhibitors translate into a powerful antiarthritic effect at well tolerated doses. Moreover, the complete absence of effect of CHR-4487 in littermate hCE-1-negative mice confirms that the limited Fig. 5 . The effect of a conventional and macrophage-targeted HDAC inhibitor on arthritis development in an anticollagen antibody-induced arthritis model conducted in wild-type or hCE-1 transgenic mice. An anticollagen antibody-induced arthritis model was conducted in littermate w/t or hCE-1 t/g mice (see Supplemental Data for breeding details). The disease was initiated on day 0 by injection of the monoclonal antibody cocktail (4 mg/mouse i.v.). Three days later, LPS (50 g/mouse) was injected (intraperitoneally) to stimulate clinical arthritis development. Drugs (SAHA, left; CHR-4487, right) were administered once daily intraperitoneally from days 0 to 11 at the doses indicated. Animals (10 per group) were scored on day 0 and from day 3 onward for signs on inflammation in one or more joints and body weights were monitored throughout. Values shown are means. For the sake of clarity, the error bars have been omitted from the graphs. The average S.E.M. for all data points whose mean score exceeded 1 in this study was Ϯ15% of the corresponding mean value. Analysis of variance with Tukey post hoc analysis was applied to determine significance of the treatments. For wild-type animals, the only treatment that was significantly different from the control group was SAHA (100 mg/kg/day), which was significant from day 6 onward. For the hCE-1-transgenic animals, SAHA (100 mg/kg/day) and CHR-4487 (3 and 10 mg/kg/day) were significantly different from controls from day 5 onward. Treatment with CHR-4487 (1 mg/kg/day) was significantly different from controls only on days 5 and 7.
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at ASPET Journals on April 19, 2017 jpet.aspetjournals.org expression of hCE-1 in monocytes and monocyte-derived cells and, to a lesser extent, granulocytes, is both essential and sufficient for therapeutic efficacy. These data underline the central role of these cells in the pathology of arthritis. More generally, they suggest that pharmacological targeting of these cells using hCE-1-hydrolysable prodrugs can retain disease efficacy and may improve the therapeutic window of a range of anti-inflammatory agents in the many diseases where these cells contribute to the pathological process. One example of this type of agent, (S-[4-(7-hydroxycarbamoylheptanoylamino)-benzylamino]-phenylacetic acid cyclopentyl ester (CHR-2845), has already entered human clinical trials as a once-a-day orally administrable agent (www.clinicaltrials. gov; identifier: NCT00820508).
A more general conclusion to be derived from the work is that strikingly cell-selective effects can be achieved by harnessing an intracellular enzyme that is able to generate a charged product. There may be other enzymes with useful expression profiles different from that of hCE-1 that can be exploited in a similar way.
